Abstract P3-04-07: The new oral SERD AZD9496 is efficacious in antagonizing ER and circumventing resistance to endocrine therapyAgostina Nardone, Rachel Schiff, Hazel M. Weir et al.|Cancer Research|2017Cited by 0
Abstract P6-20-10: Role of GPR110 in breast cancerRaksha R. Bhat, Meghana V. Trivedi, Li-Peng Qin et al.|Cancer Research|2019Cited by 0
Abstract P6-21-13: A phase II single arm trial evaluating the efficacy and safety of eribulin in combination with bevacizumab for second-line treatment of human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer (MBC) progressing after first-line therapy with bevacizumab and paclitaxelSabino De Placido, Grazia Arpino, Michelino De Laurentiis et al.|Cancer Research|2019Cited by 0
METABOLIC, HORMONAL AND SEXUAL PROFILE IN WOMEN WITH POLYCYSTIC OVARY SYNDROME BEFORE AND AFTER A SIX-MONTH TREATMENT WITH METFORMINNicola Verde, Rosario Pivonello, A. Mazzarella et al.|The Journal of Sexual Medicine|2025Cited by 0